“However, the downstream equipment presents a much bigger challenge due to the significant investment required to add ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Downstream purification continues to pressure the biopharmaceutical manufacturing industry from a capacity standpoint, with recent increases in upstream yield and titers overcoming the relatively slow ...

Osmolality is a well-established parameter for upstream bioprocessing, formulation, analytical development and QC applications throughout the manufacturing of biological drugs. A recent publication ...